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We describe a mathematical/computational model for thrombin concentration gradients
generated by procoagulant circulating tumor cells (CTCs) in flow. We examine how CTCs
enhance blood coagulation as they diffuse tissue factor-dependent coagulation enzymes
in a flow environment with vessel walls. Concentration fields of various enzymes, such
as prothrombin and thrombin, diffuse, to, and from CTCs, respectively, as they propagate
through the bloodstream. The diffusion-dependent generation of these enzymes sets up
complex time-dependent concentration fields. The CTCs are modeled as diffusing point
particles in an incompressible fluid, and we exploit exact analytical solutions based on
three-dimensional Green’s functions for unbounded domains with one wall for high reso-
lution numerical simulations. Time-dependent gradient trackers are used to highlight that
concentration fields build-up (i) near boundaries (vessel walls), (ii) in regions surrounding
the diffusing particles, and (iii) in complex time-dependent regions of the flow where fields
associated with different particles overlap. Two flow conditions are modeled: no flow, and
unidirectional constant flow. Our results indicate that the CTC-generated thrombin dif-
fuses to and persists at the blood vessel wall, and that the spatial distribution of CTCs in
flow determines local thrombin concentration.The magnitude of the diffusion gradient and
local thrombin concentration is dependent upon bulk solution concentrations of coagula-
tion factors within normal reported concentration ranges. Therefore, our model highlights
the potential to determine patient-specific risks for CTC-induced hypercoagulability as a
function of CTC number and individual patient concentration of coagulation factors.
Keywords: procoagulant circulating tumor cells, circulating tumor cells, chemical gradient tracking, tissue factor
and coagulation, prothrombin and thrombin fields, circulating tumor cell induced hypercoagulation
INTRODUCTION
Metastatic cancer accounts for the majority of deaths caused by
cancer. Metastasis is believed to result from tumor cells from a pri-
mary site, migrating toward and intravasating into a blood vessel,
navigating the blood circulation to arrive at a distant site whereby it
arrests from the blood flow, extravasates, and establishes a metasta-
tic tumor site. The process of metastasis thereby exposes a tumor
cell to a variety of new environments, and poses significant physi-
cal challenges the tumor cell must overcome if it is to successfully
metastasize.
The interactions between circulating tumor cells (CTCs) and
blood coagulation proteins have not been fully characterized.
Activation of the blood’s coagulation system has been associated
with cancer, particularly metastatic cancer, for centuries (Gay and
Felding-Habermann, 2011). The exact mechanism(s) underlying
the activation of blood coagulation in cancer remain ill-defined
(Khorana et al., 2007; Gay and Felding-Habermann, 2011). Tumor
cell expression of tissue factor (TF) has been associated with
advancing stages of cancer progression, and has been shown to
correlate with metastatic potential in vivo (Mueller et al., 1992;
Mueller and Ruf, 1998; Amirkhosravi et al., 2002). TF is a trans-
membrane glycoprotein that is normally expressed by cells outside
of the blood vasculature. The exposure of blood to TF, as occurs
in the event of a blood vessel injury, is a physiological initiator
of coagulation (Gomez and McVey, 2006; Okorie et al., 2008).
TF serves as the cell membrane receptor for and enzyme cofactor
of coagulation factor VIIa (FVIIa). In complex, TF-FVIIa activate
the extrinsic pathway of coagulation leading to the formation of
thrombin which can then convert fibrinogen to fibrin in order
to form a plug that stops bleeding at the injury site in order to
maintain blood flow and volume.
In the context of a metastasizing tumor cell, a TF-expressing
CTC may expose blood within an uninjured blood vessel to TF
(Versteeg et al., 2004; Khorana et al., 2007; Berny-Lang et al., 2011;
Otero et al., 2011; Tormoen et al., 2011). Levels of intravascular
TF correlate with cancer progression and to some extent with the
formation of pathological clots or thrombi in the veins of patients
with cancer. Thrombosis, the formation of pathological thrombi,
accounts for the second leading cause of death for patients with
cancer and constitutes a significant source of morbidity in these
patients (Versteeg et al., 2004). Anticoagulant measures taken after
a thrombotic event are effective at reducing the formation of sub-
sequent thrombi, but no current laboratory assay is capable of
predicting which patients are at risk to develop thrombosis. The
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incidence of thrombosis is known to correlate with cancer type
and tissue of origin, suggesting that the cancerous cells themselves
have a role in the formation of pathological thrombi (Blom et al.,
2005). In vitro, cancer cells are capable of independently initiat-
ing coagulation and clotting blood plasma. Similarly, functionally
blocking TF on cancer cells prevents the cell’s ability to clot blood
plasma. Therefore, mounting evidence suggests that cancer cell
expressed TF is a likely culprit for the initiation of blood coagu-
lation associated with cancer (Berny-Lang et al., 2011; Marchetti
et al., 2011, 2012; Saito et al., 2011; Yates et al., 2011; Welsh et al.,
2012).
The ability of TF to activate blood coagulation is depen-
dent upon the presence of phospholipids, suggesting that only
cell surface-expressed TF or cell membrane-derived TF bearing
microvesicles are capable of activating coagulation (Nemerson,
1968). This also indicates that the activation of coagulation by TF
is essentially a surface phenomenon, requiring coagulation factors
to transport from the blood to the surface-expressed TF in order
to participate in coagulation. In vitro, the trafficking of soluble
coagulation factors from bulk to a TF-expressing phospholipid
surface is rate-limiting with respect to enzyme activation (Gem-
mell et al., 1988; McGee et al., 1992; Hall et al., 1998). Further, TF
activity is augmented in the presence of blood flow where convec-
tive transport supplants diffusive transport as the dominant mode
of transport for coagulation factors to TF. Taken together, the abil-
ity for a TF-expressing CTC to activate blood coagulation is likely
dependent upon its spatio-temporal relationship with the blood.
In vitro, the coagulation kinetics for cancer cells in suspension
is dependent upon the number of cells added to plasma (Berny-
Lang et al., 2011; Tormoen et al., 2011; Yates et al., 2011; Welsh
et al., 2012). Further work has suggested that TF-expressing cells
in suspension show synergistic effects on their ability to initiate
and propagate coagulation, with the time to initiate coagulation
enzymes, and the rate at which these enzymes are generated cor-
relating with the average separation distance between cells rather
than the overall cell count (Tormoen et al., 2011). The effects of
spatial separation on coagulation kinetics are consistent in assays
that utilize closed systems under well-mixed conditions as well as
open systems under laminar flow. However, a CTC would expe-
rience different flow regimes if it were circulating on the arterial
side versus the venous side or if it were free-flowing or adherent
to the cell wall, and the effects that these different conditions have
on coagulation kinetics have not been established.
In this manuscript, we model the concentration of thrombin
generated by dispersed CTCs under constant laminar flow. Our
model is based upon exact solutions used in the atmospheric dis-
persion community (Stockie, 2011) whereby a source of pollution
near the ground (i.e., a smokestack) emits a pollutant which enters
the atmosphere and is dispersed and diffused downstream as a
“Gaussian plume” or a “Gaussian puff” (Stockie, 2011). We adapt
and use the solutions, which are based on a Green’s function for-
mulation for the concentration field equations (Kevorkian, 1989),
to model the dispersing and diffusing thrombin concentration
field entering the blood. Since the concentration field equations
are linear, we can superpose as many fields from each of the CTCs
as needed. We assume that the transport of coagulation factors
is diffusion-limited as viscous forces dominate inertial forces of
the cells. Our results, obtained in a simple geometry with a single
(vessel) wall, suggest that thrombin generated by a CTC collects
at the blood vessel wall and correlates with the number and spa-
tial distribution of CTCs in the blood, supporting a role for the
CTC count in predicting risk for developing thrombosis. Model-
ing and simulation of coagulation processes has been performed
(Fogelson and Tania, 2005; Fogelson, 2007; Bodnar and Sequeira,
2008; Chatterjee et al., 2010; Gregg, 2010; Leiderman and Fogel-
son, 2011), but to our knowledge, our work is the first to model
the physiologically relevant scenario of a TF-expressing cell enter-
ing into and circulating within the bloodstream and simulate its
effects on coagulation processes.
MATERIALS AND METHODS
FLUID DYNAMICS AND CONCENTRATION FIELD EQUATIONS
The computational model is based on the partial differential
equations for the diffusing concentration field, coupled with the
equations for incompressible fluid flow (Pedley, 1980; Kevorkian,
1989):
∂Ec (i)
∂t
+ Eu · ∇Ec (i) = αi∆Ec (i) + δ (Ex − Exi) (1)
E˙xi = Eu (2)
∇ · Eu = 0 (3)
ρ
(
∂ Eu
∂t
+ Eu · ∇Eu
)
= −∇p + v∆Eu (4)
Eu (Ex , 0) = Ef (Ex) (5)
Here, the concentration field associated with the ith species is
denoted Ec (i)(x , y , z ; t ), with diffusion coefficient αi. The fluid
(blood) velocity field is denoted by Eu (Ex , t ) , blood pressure
denoted p, density ρ, and each of the “i” CTCs (i= 1, . . ., n) are
located at Exi(t ), their time derivatives are denoted by the “dot”
superscript. δ in Eq. 1 is the Dirac-delta function which is zero
everywhere but where the argument is zero, which in this case
are the locations of each of the CTCs. The initial locations of the
CTCs are given by the function f (x). The diffusion coefficient in
Eq. 4 is denoted by v. Equation 4 are the Navier–Stokes equa-
tions representing the background plasma, which at this level of
model approximation we treat as an incompressible Newtonian
fluid. The flow takes place in the upper-half space, above a solid
wall which models the vessel wall, hence boundary conditions for
the concentration field and blood velocity at the wall are:
∂Ec
∂n
|wall = 0 (6)
Eu |wall = 0 (7)
The first is a no penetration condition for the concentration
field, while the second is the viscous no slip boundary condition
at the wall.
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FIGURE 1 |Two-dimensional concentration fields for 100 diffusing CTCs.
(A–C) Show evolving concentration fields at T =1, 5, 15. (D–F) Show
concentration profiles at different y -slices: y =0, 150, 300. Vessel wall is
located at y =0. (G–I) Show 3D surface plot of the concentration fields and
gives a sense of how the field diffuses in time. Boundary conditions are
discussed in text.
THE GREEN’S FUNCTION APPROACH
In this paper, we focus on the simple geometry associated with
the upper-half plane in 2D and upper-half space in 3D, making it
possible to use an analytical Green’s function formulation to form
solutions that satisfy exact boundary conditions. In 2D, with no
flow (u= 0), we use the standard Green’s function associated with
the 2D diffusion equation (Kevorkian, 1989):
c (i)
(
x , y ; t
) = Γ√
4pivt
exp
(
−(x − xi)2 −
(
y − yi
)2
4vt
)
c (i)image
(
x , y ; t
) = Γ√
4pivt
exp
(
−(x − xi)2 −
(
y + yi
)2
4vt
)
(8)
Here, each particle is placed in the upper-half plane (y> 0), at
positions (xi, yi) for i= 1, . . ., n, and image particles are placed at
(xi,−yi). The no penetration condition Eq. 6 for the concentration
field at the wall is enforced exactly, with no other explicit boundary
conditions needed.
In 3D, with flow u= constant, the corresponding Green’s
function is given by Kevorkian (1989), Stockie (2011):
c
(
r , xi , yi , zi ; t
) = QT
8(pir)3/2
exp
(
− (xi − ut )
2 + y2i
4r
)
×
[
exp
(
− (zi −H )
2
4r
)
+ exp
(
− (zi +H )
2
4r
)]
(9)
Here, r = α xi/u, is a new scaled independent variable. The
symbol QT expresses the total amount of TF expressed by the CTC.
Using these solutions as the basic building blocks for flow sim-
ulations based on Eqs 1–7, we are able to perform highly resolved
concentration-flow simulations described in Section “Results.”
CONCENTRATION FIELD GRADIENT TRACKING DIAGNOSTICS
Since the concentration field is fairly complex, we need a diag-
nostic tool to help with visualization during a simulated run. It
www.frontiersin.org September 2012 | Volume 2 | Article 108 | 3
Lee et al. Procoagulant circulating tumor cells
FIGURE 2 | Concentration profiles for 100 diffusing CTCs. (A)
Concentration profiles at y =0, 150, 300 for T =500. Note that
concentration is highest near wall. (B) Concentration profiles as a function
of T for y =0, 150, 300. Vertical dashed line separates two distinct
regimes. Left of the dashed line (0<T<3) represents the fast mixing
regime of the concentration fields due to the different CTCs, whereas right
of the dashed line (T>3) the fields from different CTCs have mixed and are
slowly diffusing.
is useful to use what we call “passive gradient trackers,” which are
diagnostic particles placed in the flow. The gradient trackers do
not disturb the flow, but move toward regions of high TF con-
centration and low TF concentration in time, as the simulation
proceeds. A schematic of one of these trackers is shown in the
upper left of Figure 3. If the tracker is placed at position (x, y,
z) at time “t,” the concentration field at that point is given by
Ec(x , y , z ; t ). The tracker then measures the concentration field at
six neighboring points in the field: Ec(x ± ε, y ± ε, z ± ε, t ), 0 <
ε << 1, and measures the differences in concentration at these
six points compared to the concentration at Ec(x , y , z ; t ). Thus,
it measures the quantities (Ec(x , y , z ; t ) − Ec(x ± ε, y , z ; t )),
(Ec(x , y , z ; t )−Ec(x − ε, y , z ; t )), (Ec(x , y , z ; t )−Ec(x , y + ε, z ; t )),
(Ec(x , y , z ; t )−Ec(x , y − ε, z ; t )), (Ec(x , y , z ; t )−Ec(x , y , z + ε; t )),
(Ec(x , y , z ; t )−Ec(x , y , z−ε; t )), and if it is seeking high concentra-
tion regions, it moves to the point yielding the largest increase in
concentration. If it seeks low concentrations, it moves to the point
yielding the largest decrease. Thus, it tracks “gradients” in the con-
centration field at each time step, and as time evolves, the particles
will gather in high/low TF concentration regions giving a useful
visual diagnostic tool. For our simulations, we use “red” track-
ers to follow increases in gradient, and “blue” trackers to follow
decreases. We note that there is an inherent timescale associated
with the tracking, which is essentially governed by the size of ε.
In the limit as this parameter goes to zero, the discrete trackers
approximate derivatives in concentrations, hence gradients.
RESULTS
TWO-DIMENSIONAL CONCENTRATION FIELDS
A two-dimensional simulation of developing concentration gra-
dients for 100 diffusing CTCs with no flow (u= 0) is shown in
Figure 1. Figures 1A–C shows the concentration field at times
T= 1, 5, 15 with u= 0 in Eq. 1. The CTCs are randomly placed
in the upper-half plane (y> 0), with the vessel wall at y = 0.
On the vessel wall, we use the no penetration condition Eq.
FIGURE 3 | Computational domain for 3D model of diffusing CTCs.
Schematic shows 3D computational domain with bottom vessel wall at
z =0. CTCs are initially placed at random initial positions and travel
downstream with the flow, which is constant. The concentration fields
diffuse as “puffs,” to model the diffusing TF which initially coats the outer
cell surface. Upper right corner of the domain shows the six directions that
are “polled” by gradient trackers placed in the flow field.
6 for the concentration field. No other explicit boundary con-
ditions are needed when using the Green’s functions formulas.
Figures 1D–F shows the concentration profiles at y = 0, 150, 300,
while Figures 1G–I shows the 3D surface plots of the concentra-
tion fields in the (x, y) plane. The CTCs are placed in the region
y> 0, while their images are placed appropriately at y< 0 (see Eq.
8) so that boundary conditions are enforced. The (dimensionless)
diffusion coefficient for each particle is taken to be αi= 1.5. We
note that here, and in all of the following simulations, equations,
and parameters are to be interpreted non-dimensionally since
explicit comparisons with in vivo experiments are not described
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FIGURE 4 |Three-dimensional concentration field simulations using four
CTCs. View is top down. Top down view of the x–y plane with four CTCs
placed randomly in the flow. Three different z -slices are shown: z =0 (wall),
z =45, z = 90 at each time T =1 (A), T =10 (B), T =40 (C), and T =75 (D).
Coloring shows that fields persist and are strongest near the wall region and
in overlap domains from different CTCs.
in this paper. The 2D simulations with no flow clearly show the
diffusing fields from each particle merging and smoothing over
time, with concentration persisting at the vessel wall because of
the no penetration boundary condition. This is seen most clearly
in Figure 2 which shows the concentration profile for T= 500 at
y= 0, 150, 300. Figure 2A shows the persistence of the highest
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FIGURE 5 |Three-dimensional concentration field simulations
using 100 CTCs. View is top down. Top down view of the x–y
plane with four CTCs placed randomly in the flow. Three different
z -slices are shown: z =0 (wall), z = 45, z = 90 at each time T =1
(A), T =10 (B), and T =40 (C), and T =75 (D). Coloring shows that
fields persist and are strongest near the wall region and in overlap
domains from different CTCs. Comparisons of the concentration
field levels with those in Figure 4 indicate that the concentration
field varies (roughly) linearly with the number of CTCs in the
domain.
concentration at the wall (y= 0). Figure 2B shows the peak
concentration at y= 0, 150, 300 as time progresses. The verti-
cal line in this figure separates two distinct temporal regimes: (i)
0<T< 3; (ii) T> 3. The first early regime represents a “rapid
mixing” regime where the concentration fields quickly merge to
form a complex combined overlap domain of fields associated with
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FIGURE 6 | Gradient trackers which move to regions of high
concentration (red) and low concentration (blue). As time
progresses [(A) T =8; (B) T = 46; (C) T=99; (D) T =167; (E)
T =220], red gradient trackers move to regions near the CTCs,
then toward regions where the fields from different CTCs overlap,
and finally toward the vessel wall where the concentration fields
persist. Blue gradient trackers move to regions of low TF
concentration.
the different sources merging together. The “long-time” regime
(T> 3) shows that the peak combined concentration field contin-
ues to decay, but rather slowly, with the peak wall concentration
(y = 0) dominating.
THREE-DIMENSIONAL CONCENTRATION FIELDS
We next performed a high resolution (exact, since we are using
the Green’s function formulation) simulation of CTCs in three-
dimensions with a constant flow velocity profile (u= constant).
Figure 3 shows the general schematic diagram with flow only
in the direction of x, with diffusing CTCs initially placed in the
domain at random heights z =H 1, H 2, H 3. The vessel wall in these
simulations is located at z = 0. Because the concentration fields are
spatially complex and time-dependent, we build in particle gra-
dient tracking capability in our code, also shown schematically in
Figure 3.
Next, we performed a 3D concentration field simulation (with-
out gradient trackers) using four CTCs, where we show a top down
z-projection view of the (x, y) plane for values z = 0 (wall), z = 45,
and z = 90, progressively in time T = 1, 10, 40, 75 in Figures 4A–
D. In order to compare with the 2D simulations, we have chosen
the same dimensionless diffusion coefficient values αi= 1.5. For
these simulations, the initial locations of the particles are (x, y,
z)= (300, 300, 45); (180, 400, 30); (300, 100, 30); (275, 200, 60).
Careful examination of the coloring of the fields indicates (i)
the persistence of the strongest concentration region near the
wall, (ii) strong concentrations in overlap domains from differ-
ent CTCs, and (iii) strong concentrations near each of the CTCs
which express TF. These numbers and results are consistent with
the experiment described in Tormoen et al. (2011) in which small
numbers TF-coated micro-spheres were placed in blood solution
and clotting time was carefully measured. Typically, in metastatic
patients, measured numbers of CTCs would be in the range of
1–100 CTCs/ml.
For a direct comparison with the 2D results, we show in
Figures 5A–D the 3D concentration field simulations using 100
CTCs placed randomly (initially). The overall concentration field
again persists near the wall, but the overall concentration field level
is higher, roughly increasing linearly with the number of CTCs in
the flow, also in agreement with results from Tormoen et al. (2011).
As the flow progresses in time, flow visualization tools become
crucial to help understand the field patterns that develop.
GRADIENT TRACKING RESULTS
To track developing TF concentration gradient patterns, we
include gradient tracking capability to our simulation. Figure 6
illustrates different time points (T = 8–220 s) as the flow pro-
gresses. The red particles move toward regions of high CTC
concentration, whereas the blue move to regions of low CTC
concentration. The patterns that develop with the red and blue
particles depend on the comparison of relative timescales as deter-
mined by the concentration field diffusion rates, αi, as well as
the timescales on which the gradient trackers move. The first
three panels in the figure clearly show the red gradient track-
ers gathering in highly concentrated regions near each of the
CTCs, lining up in elongated columnar strands. The timescale
in which these trackers locate the diffusing CTCs is short com-
pared with the timescales on which the diffusion fields spread.
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The last two figures in the panel show the particles then mov-
ing toward the vessel wall where concentration fields persist. This
movement of the trackers to the vessel walls takes place on a
longer timescale, well after the CTCs have been located in the
flow.
DISCUSSION
In this paper, we develop novel computational tools to model and
characterize the movement of diffusing thrombin fields emitted
from CTCs in flow, with the aim of scaling up the techniques to
more complex arterial environments and more complex, time-
dependent flow assumptions (Pedley, 1980). A main finding from
our model is the build-up and persistence of thrombin concen-
tration near vessel walls and in complex time-dependent overlap
regions of the flow. The build-up near walls occurs on a rel-
atively long timescale compared to the timescale in which the
concentration fields diffuse (regulated by the diffusion constants
αi). We expect this main finding to persist under more com-
plex and realistic flow geometries, as locally, near a vessel wall,
the boundary curvature should not play a big role. Furthermore,
very near the vessel wall where viscous flow boundary conditions
dominate, blood velocity magnitudes are small, so should have
minimal effects on disturbing the concentration fields that build-
up there, therefore we do not expect the inviscid fluid boundary
conditions used in this study to qualitatively alter this main find-
ing. In complex capillary beds where branching of the flow into
several different regions is the reality, we do expect the tracking
of the diffusive overlap regions of many CTCs to be more com-
putationally challenging, yet the main finding that concentration
levels are relatively high in overlap regions should remain valid.
Thrombin has several well characterized effects on endothelial cells
and platelets which are also located at blood vessel walls under
flow. In addition, the proximity of CTCs to each other deter-
mined the persistence of thrombin concentrations in the flow,
which may help explain the effect of cell count on coagulation
kinetics (Tormoen et al., 2011), suggesting that CTC counts may
hold significance to understanding the role for CTCs in activat-
ing blood coagulation. The gradient tracking capability described
here holds strong potential to aid in the understanding of the fate
of CTC-generated thrombin in more complex settings that arise
within the circulation.
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